The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2024 | Exploring the biological mechanisms driving MBL progression to CLL
Andreas Agathangelidis, PhD, Center for Research and Technology Hellas, Thermi, Greece, discusses the challenge of identifying the biological mechanisms that contribute to the progression of monoclonal B-cell lymphocytosis (MBL) to chronic lymphocytic leukemia (CLL). He highlights the need for genetic and functional analysis to understand the similarities and differences between the two entities, but emphasizes that this is an ongoing and early area of research. This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
